RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1184
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $1096 to $1184.
February 27, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on Regeneron Pharmaceuticals and raised its price target from $1096 to $1184.
The upgrade in the price target by a reputable analyst like Brian Abrahams from RBC Capital is a strong positive signal for Regeneron Pharmaceuticals. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100